-
Company Profile
![]()
F&F Holdings Co Ltd – Company Profile
F&F Holdings Co Ltd (F&F) a subsidiary of Fuji Oil Holdings Inc, manufactures and sells men's, women's and kids' wear and accessories. The company's product portfolio includes a wide range of clothing and other fashion accessories for men and women. It markets its products under the brands include MLB, MLB Kids, Stretch Angels, Duvetica and Discovery Expedition Kids. The company is engaged in building rental and license rights usage The company provides comprehensive logistics services including receiving, shipping, storing and...
Add to Basket -
Product Insights
F-A Field, South Africa
F-A upstream field is located in Indian Ocean, South Africa. The upstream field is owned by The Petroleum Oil and Gas Corporation of South Africa (SOC) Ltd. It is operated by The Petroleum Oil and Gas Corporation of South Africa (SOC) Ltd. The project started its operations in 1992. F-A Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational...
-
Product Insights
L04-F Field, Netherlands
L04-F upstream field is located in North Sea, Netherlands. The upstream field is owned by EBN BV (40%); Total E&P Netherlands BV (55.66%); Vermilion Energy Netherlands BV (4.34%). It is operated by Total E&P Netherlands BV. The project started its operations in 2003. L04-F Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end...
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s OpRegen
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Balovaptan
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Cevostamab
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Bepranemab
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Prasinezumab
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Fenebrutinib
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Ruzotolimod
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Alogabat
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Divarasib
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Tiragolumab
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Crovalimab
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Inavolisib
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Giredestrant
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Vicasinabin
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
Gannet F Field, United Kingdom
Gannet F upstream field is located in North Sea, United Kingdom. The upstream field is owned by Neo Energy (SNS) Ltd (50%); Shell U.K. Ltd (50%). It is operated by Shell U.K. Ltd. The project started its operations in 1997. Gannet F Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end years, reserves...
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Etrolizumab
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: F. Hoffmann-La Roche Ltd’s Semorinemab
Overview Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.